Danish peptide specialist Zealand Pharma has unveiled positive top-line results from the Phase III EASE 1 study of its GLP-2 analog, glepaglutide.
The novel long-acting treatment for short bowel syndrome (SBS) is designed for once or twice weekly subcutaneous delivery, via auto-injector.
The study met its primary efficacy endpoint after 24 weeks, achieving a statistically-significant reduction in weekly parenteral support volume, compared with placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze